Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-075903
Filing Date
2025-05-21
Accepted
2025-05-21 18:00:03
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 20935
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 12703
  Complete submission text file 0000950170-25-075903.txt   40385
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Subject) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-88393 | Film No.: 25974238
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 86 21 60252100
Panacea Innovation Ltd (Filed by) CIK: 0002010692 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D